Breaking News, Collaborations & Alliances

Genethon, Sarepta Choose Yposkesi as Mfg. Partner

CDMO’s capacity to produce AAV materials at large-scale will support Genethon and Sarepta’s project to take micro-dystrophin to clinical trials this year.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Yposkesi, a full-service contract development and manufacturing organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, has been selected to produce clinical and large-scale commercial AAV micro-dystrophin material within the co-development program between Genethon and Sarepta Therapeutics focused on Duchenne muscular dystrophy.   Genethon and Sarepta recently said they are extending their collaboration on developing an innovative gene therapy for D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters